Open original FDA record ↗Recall record
- FDA identifier
- Z-0316-2027
- Company in FDA record
- Tandem Diabetes Care, Inc.
- FDA classification date
- Oct 30, 2026
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 17, 2026
- Recall classification
- Class I
Reason stated in the source
Tandem Diabetes Care, Inc. ( Tandem ) has identified that certain Tandem Mobi insulin pumps may generate false-positive occlusion alarms when no actual insulin flow obstruction is present. Investigation determined that increased friction within the drive module can reduce available motor power and, under certain conditions, cause motor speed to fall below the occlusion detection threshold. As a result, the pump may incorrectly detect an occlusion condition and suspend insulin delivery. When an occlusion alarm occurs, insulin delivery remains suspended until the user acknowledges the alarm and resumes therapy. Repeated false-positive occlusion alarms, if not addressed promptly, may result in interruptions of insulin delivery that can increase the risk of elevated blood glucose levels. In severe cases, hyperglycemia may require medical intervention or hospitalization.
Source facts
- Action
- On 9/23/2026, "URGENT MEDICAL DEVICE CORRECTION" recall and correction notices were emailed to customers who were asked to do the following: Correction notices: Continue to use pump while following the instructions below. 1) Always respond to an occlusion alarm and follow the recommended troubleshooting steps in the User Guide. Acknowledge the alarm, inspect the cartridge, tubing, and infusion site for signs of damage or blockage, correct any identified condition, and resume insulin delivery. 2)Ensure that your Tandem Mobi mobile app has push notifications enabled so if the alarm does occur, you will also be notified by the app. Note: If you need assistance with enabling smartphone notifications to receive alerts from your mobile app, please click the link below to access an article on firm's support page: https://www.tandemdiabetes.com/support-center/software-and-apps/tandem-tslim-mobile-app/article/enable-smartphone-notifications-to-receive-alerts 3) Contact Tandem Customer Support if: a. You are experiencing an unusually high number of occlusion alarms, b. Occlusion alarms continue to occur after following the recommended troubleshooting steps, c. Occlusion alarms unexpectedly and repeatedly disrupt your therapy, or d. You have concerns or need assistance resolving an alarm. Tandem Customer Support can review your experience and determine whether further evaluation or action is appropriate. 4) Be prepared to use a backup method of insulin delivery. 5) Complete the online acknowledgement form using this link: https://campaign.tandemdiabetes.com/FCN-Mobi-Occlusions Recall Notices informed customers to contact firm at 1-877-801-6901 or techsupport@tandemdiabetes.com to arrange exchange. Distributors were informed: If a customer contacts you regarding this field action, please direct the customer to Tandem Customer Support at 1-877-801-6901 or techsupport@tandemdiabetes.com.
- Initiated
- 2026-09-23
- Root cause
- Process change control
- Distribution
- Worldwide - US Nationwide distribution including in the states of CA, FL, NC, OK, UT, WA, IL, PA, MN, VA, NY, IN, HI, OR, GA, MI, KS, CO, WI, SC, null, TX, NE, AZ, OH, NM, NV, MA, SD, IA, TN, ID, MD, RI, CT, NJ, ME, KY, MT, WV, VT, MS, AR, AL, DC, LA, MO, NH, PR, ND, AK, DE, WY and the country of Canada.
- Recall number
- Z-0316-2027
- Recall status
- Open, Classified
- CDRH record ID
- 222734
- FDA classified
- 2026-10-30
- Recall event number
- 99851